The potential of antibody-mediated immunity in the defence against biological weapons

Arturo Casadevall, Liise-anne Pirofski

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

Original languageEnglish (US)
Pages (from-to)1359-1372
Number of pages14
JournalExpert Opinion on Biological Therapy
Volume5
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Biological Warfare Agents
Immunity
Antibodies
Therapeutic Uses
Communicable Diseases
Vaccines
Safety
Therapeutics

Keywords

  • Antibody
  • Bioterrorism
  • Humoral
  • Immunoglobulin
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

The potential of antibody-mediated immunity in the defence against biological weapons. / Casadevall, Arturo; Pirofski, Liise-anne.

In: Expert Opinion on Biological Therapy, Vol. 5, No. 10, 10.2005, p. 1359-1372.

Research output: Contribution to journalArticle

@article{87cdf23f64de43919f9289d1a728fd05,
title = "The potential of antibody-mediated immunity in the defence against biological weapons",
abstract = "Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.",
keywords = "Antibody, Bioterrorism, Humoral, Immunoglobulin, Vaccine",
author = "Arturo Casadevall and Liise-anne Pirofski",
year = "2005",
month = "10",
doi = "10.1517/14712598.5.10.1359",
language = "English (US)",
volume = "5",
pages = "1359--1372",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - The potential of antibody-mediated immunity in the defence against biological weapons

AU - Casadevall, Arturo

AU - Pirofski, Liise-anne

PY - 2005/10

Y1 - 2005/10

N2 - Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

AB - Antibody-mediated immunity (AMI) has been used for the treatment and prevention of infectious diseases for > 100 years, and has a remarkable record of safety, efficacy and versatility. AMI can be used for defence against a wide variety of biological weapons, and passive antibody (Ab) therapy has the potential to provide immediate immunity to susceptible individuals. Recent advances in the Ab field make it possible to generate Abs with enhanced antimicrobial functions. There are significant gaps in our understanding of Ab function, such that the development of Ab-based strategies remains a largely empirical exercise. Nevertheless, the advantages inherent in the therapeutic and prophylactic use of AMI provide a powerful rationale for continued development that will undoubtedly yield many new vaccines and therapeutic Abs.

KW - Antibody

KW - Bioterrorism

KW - Humoral

KW - Immunoglobulin

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=27144497271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144497271&partnerID=8YFLogxK

U2 - 10.1517/14712598.5.10.1359

DO - 10.1517/14712598.5.10.1359

M3 - Article

VL - 5

SP - 1359

EP - 1372

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -